Suven Life Sciences Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SUVEN.BO | NBIX | I7G.F | SUPN | AMLX | 0QFP.IL | |
|---|---|---|---|---|---|---|
| Market cap | 63.96B | 16.81B | 12.79B | 1.64B | 3.69B | 4.46T |
| P/E (TTM) | — | 24.6 | 25.1 | — | — | 18.8 |
| Forward P/E | 23.5 | 13.9 | — | 6.3 | -27.0 | — |
| Price/book | 21.8 | 4.3 | 2.7 | -55.5 | 13.7 | 2.1 |
| Dividend yield | — | — | 1.05% | — | — | 7.74% |
| 1-year change | +30.58% | +7.27% | +24.26% | −11.32% | +135.96% | 0.00% |
| Today | −0.14% | +0.73% | +2.04% | +0.21% | +0.68% | +156.25% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All SUVEN.BO news ›Suven Life Sciences Bags Two Patents
Drug firm Suven Life Sciences Ltd. has been granted one product patent each by Europe and Israel for a drug used in the treatment of neuro-degenerative diseases or an ailment which primarily affects the brain. In a BSE filing today, Suven…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- ndtvprofit.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 1 articles, not a forecast.